In recent years, the clinical trial landscape in Asia and the Pacific Rim has evolved faster than in most other regions. More than half of the world’s population lives in this rapidly developing area, which includes advanced economies such as Australia, Singapore and South Korea, as well as countries with vast populations like India and China.
The attraction of being able to generate quality clinical data not only from the traditional geographies of North America and Europe but also from large pools of potential trial patients in Asia can be hard to resist, but what of the challenges? I suggest a starting point to be a critical appraisal of what the region may be able to offer any specific program. This will usually require partnering with an expert in the region, but the following brief list can act as an initial guide:
Written by Guest Writer Alek Safarian. Safarian, B.Pharm, M.B.A., is CEO of Novotech, an Australia-based CRO with operations throughout Asia-Pacific. Trained as a pharmacist, he was previously responsible for Asia-Pacific regulatory affairs operations for a global pharmaceutical company.
This article was reprinted from Volume 22, Issue 12, of The CenterWatch Monthly, an industry leading publication providing hard-hitting, authoritative business and financial coverage of the clinical research space. The Action Items section features short columns focusing on actionable or how-to advice from clinical trial professionals. To submit an Action Item, please contact email@example.com. Subscribe >>